Study Name:
A study of Pembrolizumab with concurrent chemoradiation therapy followed by Pembrolizumab with or without Olaparib in stage III non-small cell lung cancer (NSCLC).
Targeted Disease(s):
Lung Cancer
Purpose of Study:
This study is looking at how pembrolizumab with chemotherapy and radiation followed by pembrolizumab plus olaparib (or placebo for olaparib) works compared to chemotherapy and radiation followed by durvalumab.Study Dates:
July 6, 2020 - July 6, 2026
Study Location:
Nationwide
Funding Source:
Merck & Co., Inc.
ClinicalTrails.gov Identifier:
NCT04380636
